Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan

Rhea-AI Filing Summary

Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan reported selling 1,892 shares of common stock in open-market transactions. The sales on March 17, 2026 were executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, with weighted-average prices of $55.387 and $56.263 per share.

After these sales, Cowan directly holds 28,975 shares of Vaxcyte common stock. The footnotes state that all transactions were within a pre-set trading plan and that no other shares subject to a January 29, 2026 lock-up agreement were sold.

Insider Trade Summary 10b5-1

Net Seller: 1,892 shares ($105,147)

Net Sell 2 txns

Insider Cowan Elvia

Role SVP, Finance & CAO

Sold 1,892 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,487	$55.387	$82K
Sale	Common Stock	405	$56.263	$23K

Holdings After Transaction: Common Stock — 29,380 shares (Direct)

Footnotes (1)

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		1,487	D	$55.387(2)	29,380	D
Common Stock	03/17/2026		S(1)		405	D	$56.263(3)	28,975	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vaxcyte (PCVX) report for Elvia Cowan?

Vaxcyte reported that SVP, Finance & CAO Elvia Cowan sold 1,892 shares of common stock in open-market transactions. These trades occurred on March 17, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.

At what prices did Elvia Cowan sell Vaxcyte (PCVX) shares?

Cowan’s reported transactions used weighted-average prices of $55.387 and $56.263 per share. Footnotes note that actual sale prices ranged from $54.98 to $55.935 for one trade and from $56.00 to $56.42 for the other.

How many Vaxcyte (PCVX) shares does Elvia Cowan hold after the sale?

Following the reported sales, Elvia Cowan directly holds 28,975 shares of Vaxcyte common stock. This figure reflects her remaining direct ownership position after disposing of a total of 1,892 shares in the March 17, 2026 open-market transactions.

Were the Vaxcyte (PCVX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Such pre-arranged plans automate trades, reducing the significance of short-term market timing for interpreting insider activity.

Did the Vaxcyte (PCVX) insider sell any lock-up restricted shares?

No. A footnote explains that no other common shares subject to transfer restrictions under a Lock-Up Agreement dated January 29, 2026 were sold. Only the 1,892 reported shares were involved in these March 17, 2026 transactions.

What type of Form 4 transactions did Vaxcyte (PCVX) disclose?

The company disclosed two non-derivative open-market sales coded “S” in common stock for Elvia Cowan. There were no derivative exercises, gifts, or tax-withholding entries, and the net result was a reduction of 1,892 shares in her direct holdings.